NasdaqCM:ONCYBiotechs
Oncolytics Biotech Refocuses On Rare Cancers After GOBLET Enrollment Milestone
Oncolytics Biotech (NasdaqCM:ONCY) has completed patient enrollment in its Phase 1/2 GOBLET study.
The company is moving ahead with pivotal trials in squamous cell anal cancer and metastatic colorectal cancer.
Management is shifting clinical focus and resources toward these rare cancer indications and planning FDA interactions related to potential approval pathways.
Oncolytics Biotech focuses on cancer therapies, and the GOBLET study sits at the center of that effort. With enrollment now...